By Dr. Asnat Raziel, bariatric surgeon specializing in obesity treatment, metabolic health and healthy longevity; Director of the Multidisciplinary Center for Obesity Treatment, Assia Medical, Assuta Ramat HaChayal, Tel Aviv
Wegovy pill FDA approval: why it is a defining moment
The Wegovy pill FDA approval, granted by the US Food and Drug Administration on December 22, 2025, opened a new era. For the first time, a GLP-1 drug for obesity comes as a daily pill. The pill contains semaglutide, the same active ingredient as the Wegovy injection. As a result, its effectiveness is very close to that of the shot.
Even so, obesity remains a chronic disease in the age of pills. It still requires a diagnosis, a personalized plan and long-term follow-up. In this article, I will explain what was approved, which data it rests on, and what has changed since.
Higher injectable doses are also changing the picture, as I explain in the Wegovy 7.2 mg approval.
What exactly was approved
The FDA approved oral semaglutide at a maintenance dose of 25 mg a day. It is intended for adults with obesity, or with overweight plus a related medical condition. In addition, the label includes a reduced risk of major heart events in people who already have heart disease. In other words, the pill received the same adult indications as the injection.
It is important to tell it apart from Rybelsus. Rybelsus is an older semaglutide pill that is approved for type 2 diabetes only. The differences between the two are explained in the article Rybelsus vs. the Wegovy pill.
The OASIS 4 trial: the data behind the Wegovy pill FDA approval
The main basis for the approval is the OASIS 4 trial, published in the NEJM (New England Journal of Medicine). It enrolled 307 adults with overweight or obesity and without diabetes. Of these, 205 received the pill and 102 received a placebo. All participants also received support for lifestyle change.
After 64 weeks, people on the pill lost an average of 13.6% of their body weight. By contrast, the placebo group lost 2.2%. In an analysis that assumed continuous use as directed, weight loss reached 16.6%. Put simply, people who stick with treatment get most of the benefit. These results are close to those of the Wegovy injection at 2.4 mg. For a deeper look at the trial itself, see my article on the OASIS 4 results.
Why the pill dose is so much higher
The weekly injection dose is 2.4 mg. In the pill, however, the daily dose is 25 mg. The reason is poor absorption through the digestive tract. Most of the drug never reaches the bloodstream, so a much larger amount is needed.
To improve absorption, the pill includes a carrier called SNAC. It protects the drug in the stomach and helps it cross the stomach wall. That is also why the dosing instructions are so strict.
How to take the pill
How you take it is part of the treatment itself. The instructions are similar to those for Rybelsus:
- In the morning, on an empty stomach.
- With only a little water, up to 120 ml.
- Swallow the pill whole.
- Wait half an hour before eating, drinking or taking other medicines.
Treatment starts at a low dose of 1.5 mg. After that, the dose rises gradually to 4 mg, then 9 mg and finally 25 mg. If you are moving from the injection to the pill, you will find a detailed explanation in the article on switching from the injection to the pill.
Side effects and what we learned from them
The common side effects involve the digestive system: nausea, vomiting, diarrhea and constipation. In OASIS 4, they occurred in 74.0% of pill users. By comparison, the rate in the placebo group was 42.2%. In most cases, the symptoms were mild to moderate.
That said, adherence in the real world may be lower than in the trial. The reasons are the side effects and the need to take the pill precisely every morning. For this reason, gradual dose increases and close follow-up are especially important. A full review appears in the article on Wegovy side effects.
Price and availability since the Wegovy pill FDA approval
The pill launched in the United States on January 5, 2026. For self-pay patients, the 1.5 mg and 4 mg doses cost $149 a month. The 9 mg and 25 mg doses cost $299 a month. Later, from mid-April, the price of the 4 mg dose rose to $199.
Demand was higher than expected. According to the company, by June 2026 more than three million prescriptions had been written. Moreover, over 80% of new prescriptions went to people who had not been on GLP-1 treatment before. In Europe, the European Commission approved the pill in July 2026.
And what about Israel?
The Wegovy pill arrived in Israel in November 2026, and it is available through Form 29C, the Israeli Ministry of Health form for importing a medicine for a named patient. Even earlier, in September 2026, a different pill, Foundayo (orforglipron), reached Israel. You will find details in the article on Foundayo in Israel. The economic meaning of the pills is discussed in the article on the weight-loss drug market. For a practical guide to using it here, see the Wegovy pill in Israel.
Who the pill suits best
The pill is especially suitable for people with obesity who are afraid of needles. It also suits those who prefer a daily-pill routine, much like blood pressure medicine. Likewise, people who stopped the injection because self-injecting was hard can consider the pill. On the other hand, people who find it hard to give up their morning coffee for half an hour may lose some of the effect. In that case, a weekly injection is far more convenient. A broader comparison of the options appears in the article pill or injection for obesity.
Not a magic pill
The pill removes an important barrier: the fear of injections. However, it is not a magic solution. The best results come with a tailored diet, physical activity, good sleep and emotional support. In addition, weight tends to come back when treatment stops. That is why it is important to plan treatment as a long-term process, with a doctor who knows the field.
Bottom line on the Wegovy pill FDA approval
The Wegovy pill FDA approval is a big step for people who struggle with injections. The pill led to an average weight loss of 13.6%, and it created huge demand within the first months. In the end, success depends on a personalized plan, correct use and medical follow-up over time.
The information in this article is general and does not replace personal medical advice.
References
Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity
FDA Approves Oral Semaglutide as First GLP-1 Pill for Weight Loss
Novo launches Wegovy weight-loss pill for sale in US
No more injections? New weight-loss pill to launch in Israel next week
The OASIS 4 trial was funded by Novo Nordisk, the drug’s manufacturer.
